Lagos

Researchers are comparing two treatments for patients newly diagnosed with early to moderate primary open-angle glaucoma (POAG) or ocular hypertension (OHT) at Lagos State University Teaching Hospital in Nigeria. The study aims to find out if selective laser trabeculoplasty (SLT) is as effective and safe as 0.005% latanoprost eye drops in lowering eye pressure when used as the first treatment. It will also assess how these treatments affect patients' quality of life. Participants are randomly assigned to one of two groups. One group will use 0.005% latanoprost eye drops every night at 9:00 pm for three months. The other group will receive a single session of SLT laser treatment. Eye pressure will be checked regularly during the three months following treatment. Any side effects will be recorded at each follow-up visit. Throughout the study, participants will have their eye pressure measured multiple times to track changes from the beginning of the study to three months. Safety and side effects will be monitored carefully. The total study period is twelve months, including data collection and analysis. Written consent will be obtained, and all participant information will be kept confidential.

This research aims to evaluate and improve how appendicitis, the most common emergency surgery, is managed worldwide. Appendicitis requires timely diagnosis and treatment to prevent complications and reduce healthcare costs. By using appendicitis as a "tracer condition," the study examines emergency care systems across different countries, focusing on access to care, treatment quality, and efficiency. The goal is to find gaps in emergency surgical care, especially in low- and middle-income countries, to guide future improvements. The study will collect data from about 500 hospitals globally between February 3 and May 25, 2025. Each hospital will gather information over 14 days on patients undergoing appendicectomy, which includes open, laparoscopic, and robotic surgeries, as well as cases converted from minimally invasive to open surgery. The study also includes two sub-studies: one exploring sustainability and waste management in operating rooms, and another examining the financial impact of appendicectomy on patients, particularly in lower-income settings. Participants include all patients having appendicectomy for suspected or confirmed appendicitis during the study period. Data will be collected from routine health records without additional follow-up. Researchers will measure key outcomes such as time to surgical assessment, rates of laparoscopic surgery, postoperative complications, length of hospital stay, and financial costs to patients. The study aims to capture data on about 14,000 patients to understand how differences in hospital resources affect care and outcomes worldwide.

Researchers are evaluating the safety and activity of a new medicine called etavopivat in children aged 12 to 16 years with sickle cell disease who are at higher risk for stroke. The study focuses on how etavopivat affects blood flow velocity in brain arteries, measured by transcranial Doppler (TCD) ultrasound. Participants are divided into two groups based on their TCD results and whether they are receiving hydroxyurea, a medication commonly used in sickle cell disease treatment. The study is a Phase 2, open-label trial aiming to better understand etavopivat’s effects in this pediatric population. Participants will take 400 mg of etavopivat daily, given as two 200 mg tablets by mouth, which can be taken with or without food. The treatment period lasts 52 weeks (one year). One group includes participants with conditional or abnormal TCD results who are not taking hydroxyurea, while the other includes those with similar TCD results who are on a stable dose of hydroxyurea. After the 52-week treatment, participants may have the option to join a 48-week extension phase to continue evaluating the safety of etavopivat. If appropriate, participants might also be offered to join a separate study to keep receiving etavopivat after completing these phases. Throughout the study, participants will visit the clinic regularly for assessments, including TCD ultrasound to measure blood flow velocities in specific brain arteries at baseline and week 12. Researchers will monitor safety and treatment effects closely. The primary outcome is the change in the highest blood flow velocity measured by TCD in any of the left or right internal carotid or middle cerebral arteries. Caregivers and participants will be involved in ongoing evaluations to ensure safety and adherence during the study's full duration and optional extension period.

The trial investigates the safety, tolerability, effectiveness, and how the body processes and responds to osivelotor in people with sickle cell disease (SCD). This Phase 2/3, multicenter study involves adults and adolescents with SCD, aiming to find the best dose and compare osivelotor to a placebo. The study also includes a long-term extension to assess ongoing safety and blood-related effects. Osivelotor is given orally as tablets. The study has three parts: Part A focuses on determining a safe and effective dose in adults; Part B compares osivelotor to placebo in adults and adolescents over 48 weeks; and the Open Label Extension (OLE) offers continued treatment to those who completed Part B to monitor long-term safety and responses. Participants will be monitored throughout the study periods with assessments of safety, tolerability, and treatment effects. These include evaluations at 12 weeks (Part A), 48 weeks (Part B), and approximately 24 months after the last participant joins (OLE). Researchers will track blood values, side effects, and disease-related events to understand how the drug works and its impact on SCD over time.

Researchers are evaluating the long-term safety and effectiveness of etavopivat, a new oral medicine being developed to treat inherited blood disorders such as sickle cell disease and thalassemia. These disorders affect hemoglobin, the protein responsible for carrying oxygen in the body. This phase 3 study aims to monitor how well etavopivat works and its safety profile over an extended period. Participants will receive one of three forms of etavopivat (A, B, or C) as oral doses. The study is open-label and multicenter, involving adults, adolescents, and children who have previously completed treatment in an etavopivat parent study and continue to benefit clinically. The treatment period can last up to 264 weeks but may end earlier if etavopivat is approved in the participant's country. During the study, researchers will track the number of treatment-emergent adverse events and adverse reactions for each participant by indication and age group from baseline through the end of the study, which can last up to 316 weeks. Participants' safety and response to long-term treatment will be closely monitored throughout this period.

Researchers are evaluating how well etavopivat works to reduce the number of vaso-occlusive crises (painful blood vessel blockages) in adolescents and adults living with sickle cell disease. The study also aims to assess if etavopivat can decrease organ damage, improve exercise tolerance, and reduce fatigue. This is a global Phase 3 study involving participants aged 12 years and older with confirmed sickle cell disease. The study is randomized, double-blind, and placebo-controlled to ensure accurate evaluation of the treatment effects. Participants will receive either etavopivat or a matching placebo by mouth. Which treatment they receive is determined randomly. The study will last about two years, during which participants will take the assigned medication and be monitored closely. Etavopivat is an investigational drug currently under evaluation in multiple studies for sickle cell disease. During the study, participants will have regular assessments including documentation of vaso-occlusive crisis events, blood tests, and physical evaluations. Researchers will track the number of crises that require medical attention over a 52-week period, as well as measures of organ health, exercise ability, and fatigue. Safety and overall health will be monitored throughout the study, with the total participation time lasting approximately two years.

Researchers are evaluating etavopivat, a once-daily oral medicine, in children and adolescents with sickle cell disease. This phase 1/2 study aims to understand the safety of etavopivat and how it behaves in the bloodstream, while also exploring potential benefits for patients. The study focuses on pediatric patients aged from 6 months to under 18 years with confirmed sickle cell disease and severe symptoms. Participants will receive etavopivat tablets by mouth once daily for a continuous 96-week treatment period. After completing treatment, there will be a final study visit four weeks later to assess any lasting effects. The study includes monitoring drug levels in the blood at various points to measure how etavopivat is processed by the body. During the study, participants will have regular assessments to monitor safety and treatment effects, including lab tests to measure drug concentration, and tracking of any side effects or adverse events. Researchers will observe the number of dose changes, interruptions, and early discontinuations throughout the 24-week primary period and beyond. The total study duration includes the 96-week treatment and a 4-week follow-up, with comprehensive monitoring of health status and medication impact.

This research aims to study breast cancer treatment specifically for Nigerian women who have HER2-positive breast cancer. The focus is on evaluating the effectiveness and safety of anti-HER2 therapies given before and after surgery. The study is designed to understand how these targeted treatments work in this population and to improve cancer care. Participants will receive a combination of anti-HER2 drugs, including trastuzumab with pertuzumab (PHESGO), alongside chemotherapy drugs such as docetaxel and trastuzumab emtansine. Hormone therapies like tamoxifen, letrozole, and goserelin are also part of the treatment plan. Treatments are given both before surgery (neoadjuvant phase) and after surgery (adjuvant phase) to assess their impact on the cancer. Throughout the study, participants will undergo regular assessments including biopsies, ultrasounds, blood tests, and heart function tests to monitor safety and treatment effects. Researchers will track the pathological complete response over a 10-year period to measure long-term outcomes. The study includes thorough safety checks and follow-up visits to ensure participants' well-being during and after treatment.

This research aims to promote cervical cancer screening and follow-up treatment for women living with HIV in Nigeria, a group at higher risk for cervical cancer. It focuses on adapting and implementing a tailored program called MoMent, originally designed as a peer support system for HIV care, to include home-based cervical cancer screening. The study also seeks to evaluate the program's reach, effectiveness, adoption, and fidelity, and to understand barriers and facilitators for sustaining the program long term. The study uses the MoMent program, which pairs trained HIV-positive women called Mentor Mothers with newly diagnosed women to support their care. This program is being adapted to promote home-based HPV screening using the GeneXpert HPV test. Stakeholders including women living with HIV, peer counselors, clinical managers, and policymakers contribute to tailoring the program. The study will enroll about 1,500 women and follow them through the adapted program to assess how well it works and how it can be maintained and scaled. Participants will perform vaginal self-collection for HPV screening and provide informed consent. Researchers will measure the program's reach, effectiveness, adoption, and fidelity at the start, 6 months, and 18 months. The study also includes a post-implementation evaluation to identify challenges and enablers for sustaining the program. Overall participation spans this evaluation timeline with ongoing monitoring and stakeholder feedback to improve cervical cancer control for women living with HIV in Nigeria.

Neonatal hypothermia is common in low-resource settings, especially in countries with high newborn death rates. Untreated hypothermia can cause serious health problems and reduce the effectiveness of treatments for other newborn conditions. This research evaluates a new warming mattress called the Celsi Warmer, designed to be affordable, durable, and easy to use to help treat hypothermic newborns in such settings. The study takes place at the Lagos University Teaching Hospital in Nigeria and aims to see how well the Celsi Warmer works in this environment. The study involves a single group of up to 90 newborns treated with the Celsi Warmer. A trained clinician will place a temperature sensor on each infant's abdomen using a special belt following the device instructions. The infant's temperature will be monitored continuously before, during, and after the warming treatment to evaluate the device's effectiveness in safely raising body temperature. Participants will be newborns admitted to the neonatal ward with moderate to severe hypothermia who cannot receive Kangaroo Mother Care for various reasons. Their temperature and health will be closely monitored throughout the intervention. The main outcome measured is the comparison of the infant's temperature to the standard rewarming methods over one year. Safety and performance of the warming mattress will be assessed to understand its potential benefits in low-resource hospitals.